All News
Filter News
Found 772 articles
-
Red Biotechnology Market Size to Garner Around USD 618.64 Billion by 2032
11/16/2023
The global red biotechnology market size is predicted to garner around USD 618.64 billion by 2032 and is expanding at a CAGR of 5.41% from 2023 to 2032.
-
Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk
11/11/2023
Alnylam Pharmaceuticals, Inc. announced positive results from the KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen in development for the treatment of patients with hypertension and high cardiovascular risk.
-
Antibodies Drug Market Size to Surpass USD 6,05,800 Million by 2032
11/9/2023
The global antibodies drug market size reached USD 2,00,180 million in 2022 and is estimated to surpass around USD 6,05,800 million by 2032, growing at a CAGR of 10.8% between 2023 and 2032.
-
With headwinds in the wider biotech sphere, the third quarter showed continuing vulnerabilities in the COVID space while the weight-loss drugs drove blockbuster sales.
-
Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update
11/7/2023
Replimune Group, Inc. announced financial results for the fiscal second quarter ended September 30, 2023 and provided a business update.
-
BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update
11/6/2023
BioNTech SE reported financial results for the three and nine months ended September 30, 2023, and provided an update on its corporate progress.
-
Biotheus Enters Into Strategic Partnership with BioNTech to Develop and Commercialize Bispecific Antibody Candidate Targeting PD-L1 and VEGF in Multiple Solid Tumor Indications
11/6/2023
Biotheus Inc. ("Biotheus") today announced that the company has entered into an exclusive global license and collaboration agreement under which BioNTech will be developing, manufacturing and commercializing PM8002 globally ex-Greater China, whereas Biotheus retains the rights to exploit PM8002 in Greater China.
-
While Regeneron Pharmaceuticals reported better-than-expected third-quarter results, sales of the company’s lead drug Eylea declined amid increased competition.
-
Regeneron Reports Third Quarter 2023 Financial and Operating Results
11/2/2023
Regeneron Pharmaceuticals, Inc. announced financial results for the third quarter of 2023 and provided a business update.
-
Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity
11/2/2023
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2023 and reviewed recent business highlights.
-
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
10/26/2023
Pfizer Inc. and BioNTech SE announced positive topline results from a Phase 1/2 study evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age.
-
Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
10/25/2023
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) today announced additional positive interim results for the ongoing single ascending dose portion of the Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) in development for the treatment of Alzheimer’s disease and cerebral amyloid angiopathy (CAA).
-
Alnylam Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine
10/25/2023
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that results from the APOLLO-B Phase 3 study of investigational patisiran in patients with the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis were published online in the New England Journal of Medicine (NEJM).
-
BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023
10/23/2023
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced follow-up data from its ongoing first-in-human Phase 1/2 trial (NCT04503278; 2019-004323-20) evaluating the safety and efficacy of the Company’s Claudin-6 (CLDN6)-directed CAR-T cell therapy candidate BNT211 in patients with CLDN6-positive refractory/relapsed solid tumors.
-
BioNTech to Report Third Quarter Financial Results and Corporate Update on November 6, 2023, And to Host Innovation Series Day on November 7, 2023
10/23/2023
BioNTech SE will announce its financial results for the third quarter 2023 on Monday, November 6th, 2023.
-
BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication
10/19/2023
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that the first patient has been treated in a Phase 2 clinical trial evaluating the mRNA-based individualized neoantigen-specific immunotherapy (iNeST) candidate autogene cevumeran (also known as BNT122, RO7198457) in resected pancreatic ductal adenocarcinoma (PDAC).
-
Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry
10/18/2023
Meharry Medical College, along with partners Regeneron Genetics Center®, AstraZeneca, Novo Nordisk, and Roche, announced the launch of the Together for CHANGE™ initiative to create better health care and outcomes for all.
-
Update Regarding Pfizer’s Statement on COMIRNATY-Related Write-Offs
10/16/2023
On October 13, 2023, Pfizer Inc., a collaboration partner of BioNTech SE, announced a non-cash charge for inventory write-offs and other charges related to COMIRNATY of $0.9 billion.
-
BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023
10/16/2023
BioNTech SE will present data across its oncology pipeline, covering multiple solid tumor types and novel mechanisms of action, at the European Society for Molecular Oncology Congress 2023 in Madrid, Spain from October 20-24, 2023.
-
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
10/9/2023
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) in response to the Company’s supplemental New Drug Application (sNDA) for patisiran for the treatment of the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis.